60 Degrees Pharmaceuticals (SXTP)
Market Price (3/30/2026): $1.45 | Market Cap: $1.3 MilSector: Health Care | Industry: Biotechnology
60 Degrees Pharmaceuticals (SXTP)
Market Price (3/30/2026): $1.45Market Cap: $1.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -287% | Weak multi-year price returns2Y Excs Rtn is -119%, 3Y Excs Rtn is -162% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -838% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 92% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 43% | |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -57% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -720%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -729% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics. Themes include Infectious Disease Drug Development, and Tropical Disease Therapeutics. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -582% | |
| High stock price volatilityVol 12M is 209% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 53% | ||
| Key risksSXTP key risks include [1] substantial doubt about its ability to continue as a going concern due to high cash burn and shareholder dilution, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -287% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 92% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -57% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics. Themes include Infectious Disease Drug Development, and Tropical Disease Therapeutics. |
| Weak multi-year price returns2Y Excs Rtn is -119%, 3Y Excs Rtn is -162% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -838% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 43% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -720%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -729% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -582% |
| High stock price volatilityVol 12M is 209% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 53% |
| Key risksSXTP key risks include [1] substantial doubt about its ability to continue as a going concern due to high cash burn and shareholder dilution, Show more. |
Qualitative Assessment
AI Analysis | Feedback
60 Degrees Pharmaceuticals (SXTP) stock has lost about 65% since 11/30/2025 because of the following key factors:
1. Poor Financial Performance and Ongoing Operating Losses.
60 Degrees Pharmaceuticals has consistently reported significant net losses and high operating expenses, undermining investor confidence. For the third quarter of 2025, announced on November 13, 2025, the company reported a net loss attributable to common shareholders of approximately $2.44 million, or ($0.66) per share. The company also incurred a gross loss of approximately $100,000 in Q3 2025, attributed to a one-time inventory write-off. Annually, the company has a trailing EPS of -$13.88 and a recorded net income of -$7.95 million. These persistent losses highlight a challenging financial outlook and a struggle to achieve profitability.
2. Implementation of a Reverse Stock Split.
On October 10, 2025, stockholders approved a reverse stock split at a ratio between 1-for-3 and 1-for-10. By March 2026, a 1-for-4 reverse stock split was in effect. Reverse stock splits are often enacted by companies with deeply depressed share prices to meet exchange listing requirements, and they typically signal underlying financial distress. Such actions frequently lead to a further erosion of investor sentiment and continued stock price depreciation, as they do not fundamentally improve the company's business operations or financial health.
Show more
1. Poor Financial Performance and Ongoing Operating Losses.
60 Degrees Pharmaceuticals has consistently reported significant net losses and high operating expenses, undermining investor confidence. For the third quarter of 2025, announced on November 13, 2025, the company reported a net loss attributable to common shareholders of approximately $2.44 million, or ($0.66) per share. The company also incurred a gross loss of approximately $100,000 in Q3 2025, attributed to a one-time inventory write-off. Annually, the company has a trailing EPS of -$13.88 and a recorded net income of -$7.95 million. These persistent losses highlight a challenging financial outlook and a struggle to achieve profitability.
2. Implementation of a Reverse Stock Split.
On October 10, 2025, stockholders approved a reverse stock split at a ratio between 1-for-3 and 1-for-10. By March 2026, a 1-for-4 reverse stock split was in effect. Reverse stock splits are often enacted by companies with deeply depressed share prices to meet exchange listing requirements, and they typically signal underlying financial distress. Such actions frequently lead to a further erosion of investor sentiment and continued stock price depreciation, as they do not fundamentally improve the company's business operations or financial health.
Show more
Stock Movement Drivers
Fundamental Drivers
The -64.6% change in SXTP stock from 11/30/2025 to 3/29/2026 was primarily driven by a -64.6% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.24 | 1.50 | -64.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 0.0% |
| P/S Multiple | 4.1 | 1.5 | -64.6% |
| Shares Outstanding (Mil) | 1 | 1 | 0.0% |
| Cumulative Contribution | -64.6% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SXTP | -64.6% | |
| Market (SPY) | -5.3% | 14.9% |
| Sector (XLV) | -8.7% | 3.0% |
Fundamental Drivers
The -73.4% change in SXTP stock from 8/31/2025 to 3/29/2026 was primarily driven by a -59.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.64 | 1.50 | -73.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 47.1% |
| P/S Multiple | 3.2 | 1.5 | -54.9% |
| Shares Outstanding (Mil) | 0 | 1 | -59.9% |
| Cumulative Contribution | -73.4% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SXTP | -73.4% | |
| Market (SPY) | 0.6% | 12.9% |
| Sector (XLV) | 5.2% | 3.0% |
Fundamental Drivers
The -79.3% change in SXTP stock from 2/28/2025 to 3/29/2026 was primarily driven by a -86.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.24 | 1.50 | -79.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 92.0% |
| P/S Multiple | 1.8 | 1.5 | -18.8% |
| Shares Outstanding (Mil) | 0 | 1 | -86.7% |
| Cumulative Contribution | -79.3% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SXTP | -79.3% | |
| Market (SPY) | 9.8% | 0.4% |
| Sector (XLV) | -2.1% | 0.4% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SXTP | ||
| Market (SPY) | 69.4% | -0.4% |
| Sector (XLV) | 18.4% | -2.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SXTP Return | - | - | -78% | -89% | -92% | -27% | -100% |
| Peers Return | -22% | -65% | -60% | 43% | -6% | -9% | -87% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| SXTP Win Rate | - | - | 33% | 25% | 33% | 33% | |
| Peers Win Rate | 40% | 28% | 32% | 40% | 53% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| SXTP Max Drawdown | - | - | -88% | -94% | -92% | -30% | |
| Peers Max Drawdown | -35% | -72% | -67% | -50% | -46% | -17% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NVAX, EBS, SIGA, TNXP, INO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
SXTP has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to NVAX, EBS, SIGA, TNXP, INO
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About 60 Degrees Pharmaceuticals (SXTP)
We are a growth-oriented specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir. Our mission is to address the unmet medical need associated with infectious diseases, through the development and commercialization of new small molecule therapeutics, focusing on synthetic drugs (made by chemists in labs, excluding biologics) with good safety profiles based on prior clinical studies, in order to reduce cost, risk, and capitalize on existing research. We are seeking to expand Arakoda’s use for malaria prevention and to demonstrate clinical benefit for other disease indications. We are further testing the viability of another product (Celgosivir) to determine whether to advance it into further clinical development, and may seek to develop and license other molecules in the future. Celgosivir is being developed for COVID-19, RSV and Dengue. Our principal executive offices are located at 1025 Connecticut Avenue NW Suite 1000, Washington, D.C.
AI Analysis | Feedback
An emerging Gilead Sciences, with a specific focus on small molecule therapeutics for infectious diseases.
AI Analysis | Feedback
- Arakoda: A regulatory-approved malaria preventative treatment available on the market since late 2019.
- Celgosivir: A product currently in development for COVID-19, RSV, and Dengue.
AI Analysis | Feedback
60 Degrees Pharmaceuticals (SXTP) primarily sells its prescription pharmaceutical products, such as Arakoda, to other companies rather than directly to individuals. The provided company description does not list the names of specific customer companies. However, based on the nature of its products (a malaria preventative treatment and other infectious disease therapeutics), its major customers would typically fall into these categories:
- Government Agencies: Especially military organizations (e.g., Department of Defense or similar bodies in other countries) for use by personnel deployed in malaria-endemic regions, and potentially public health agencies or international aid organizations.
- Pharmaceutical Wholesalers and Distributors: These companies purchase drugs from manufacturers and then supply them to pharmacies, hospitals, and other healthcare providers.
- Hospitals and Pharmacies: These healthcare institutions and retail outlets procure the medication to dispense to patients requiring malaria prevention.
AI Analysis | Feedback
nullAI Analysis | Feedback
Geoffrey Dow, Chief Executive Officer, President, and Director
Geoffrey Dow is a co-founder of 60 Degrees Pharmaceuticals, Inc. in 2010. He has over 20 years of experience in product development for tropical diseases, including 13 years in leadership and advisory roles within the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow was instrumental in securing FDA-regulatory approval for tafenoquine (Arakoda) for malaria prophylaxis.
Tyrone Miller, Chief Financial Officer and Treasurer
Tyrone Miller joined 60 Degrees Pharmaceuticals in 2014 and has served in various capacities, including Chief Financial Officer and Treasurer. He has experience raising over $6 million in external financing and establishing multinational financial reporting systems. Mr. Miller is also the founder and Principal of Miller Tax & Advisory since 2011, where he advises business owners on accounting, financial, and tax matters. He is a Certified Public Accountant.
Bryan Smith, Chief Medical Officer
Bryan Smith is a medical doctor with over 30 years of experience in governmental research and leadership, including serving as a retired military colonel. He joined 60 Degrees Pharmaceuticals in 2016 and possesses expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development, and translational medicine. Dr. Smith also holds a position as Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC, and previously served as Chief Medical Officer for Amivas LLC.
Kristen Landon, Chief Commercial Officer
Kristen Landon joined 60 Degrees Pharmaceuticals in 2024, bringing over 26 years of experience in building and transforming pharmaceutical brands. Her background includes launching and relaunching more than a dozen brands, many achieving peak revenues exceeding $100 million, across diverse therapeutic categories such as women's health, infectious disease, dermatology, nephrology, and hematology/oncology.
Jennifer Herz, Director
Jennifer Herz serves as a head consultant for 60 Degrees Pharmaceuticals and possesses over 20 years of experience in commercial, business development, and scientific affairs within the bio-pharma industry, with a particular focus on vaccines. She was the first Managing Director of Sanofi Pasteur in Australia, where she played a key role in developing the company and commercially launching five new vaccines. Ms. Herz is also a co-founder and director at Biointelect Pty.
AI Analysis | Feedback
```htmlThe key risks for 60 Degrees Pharmaceuticals (SXTP) are primarily centered around the inherent challenges of pharmaceutical development and commercialization.
- Clinical Development and Regulatory Approval Risk: The company's future growth is highly dependent on the successful development, clinical trials, and regulatory approval of its pipeline products, including new products containing Tafenoquine (the active ingredient in Arakoda) and Celgosivir. Celgosivir is explicitly stated to be "further testing the viability... to determine whether to advance it into further clinical development," indicating it is in an early and high-risk stage. The process of drug development is complex, costly, and has a high rate of failure, meaning there is significant risk that these products may not achieve regulatory approval or may take longer and cost more than anticipated.
- Commercialization and Market Reliance on Arakoda: While Arakoda is an approved malaria preventative treatment, the company is "seeking to expand Arakoda’s use for malaria prevention and to demonstrate clinical benefit for other disease indications." This suggests that the current commercial success of Arakoda may not be sufficient to meet the company's growth objectives, and its financial performance is heavily reliant on the continued and expanded market acceptance of this single primary product. Failure to expand Arakoda's use or achieve strong market penetration could significantly impact revenue and profitability.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for 60 Degrees Pharmaceuticals' main products and services are detailed below:
Arakoda (Tafenoquine)
- For Malaria Prevention: The global antimalarial drugs market, which includes prevention, was valued at approximately US$ 1.07 billion in 2024 and is projected to reach around US$ 1.67 billion by 2034.
- For Human Babesiosis: 60 Degrees Pharmaceuticals estimates the maximum annual addressable market (TAM) for Arakoda for the treatment of human babesiosis in the U.S. to be 380,000 patients, generating $245 million in sales annually. The cumulative TAM through patent expiration in 2035 is projected to be 1.17 million patients, equating to $1.1 billion.
Celgosivir
- For COVID-19 Treatment: The global COVID-19 therapeutics market was valued at approximately $9.36 billion in 2024. However, this market is expected to significantly decline to $541.44 million by 2029 globally. The antiviral segment, which includes Celgosivir, accounted for $2.76 billion of the global market in 2024. The U.S. market for COVID-19 therapeutics constituted $5.09 billion in 2024.
- For RSV (Respiratory Syncytial Virus) Treatment: The global respiratory syncytial virus treatment market was valued at approximately USD 2.39 billion in 2024 and is projected to reach USD 8.33 billion by 2033. In the U.S., the demand for human RSV treatment is projected to grow from USD 674.6 million in 2025 to USD 1,342.6 million by 2035.
- For Dengue Treatment: The global dengue fever treatment market was estimated at approximately USD 2.14 billion in 2024 and is projected to grow to USD 3.86 billion by 2035. The North America dengue treatment market was valued at USD 158.10 million in 2024 and is projected to reach USD 348.19 million by 2032.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for 60 Degrees Pharmaceuticals (SXTP) over the next 2-3 years:- Expanded Sales and Marketing for Arakoda in Malaria Prevention: The company is actively expanding its commercial efforts for Arakoda, its FDA-approved malaria preventative treatment. This includes doubling the number of inside sales representatives, forming partnerships such as with GoodRx to broaden point-of-sale visibility and offer patient savings, and enhancing digital marketing campaigns to increase prescriber awareness and engagement. A new 8-count bottle format has also been released to cater to short-duration travelers, expanding access through major retail pharmacies and platforms like Amazon Pharmacy. Additionally, a partnership with Runway Health, commencing in April 2026, aims to provide international travelers with direct access to Arakoda through a telehealth platform. These initiatives are built on a commercial pilot that demonstrated increasing market demand and led to a 223% year-over-year increase in Q3 2025 net product revenue for Arakoda.
- Expansion of Arakoda into the Babesiosis Treatment Market: 60 Degrees Pharmaceuticals is pursuing the repositioning of Arakoda (tafenoquine) for the treatment of babesiosis, a tick-borne disease currently lacking FDA-approved treatments. The company received IRB approval for a Phase II clinical study of Arakoda for chronic babesiosis, with patient enrollment expected to begin in Q3 2025. Recent expanded-use clinical trials have shown promising results, with all three enrolled patients cured of relapsing babesiosis after completing the tafenoquine regimen, suggesting a high cure rate. The company estimates a significant addressable market exceeding 400,000 patients for Arakoda in babesiosis treatment through its patent protection period. The CEO has highlighted expanding Arakoda's label to include babesiosis as a key strategy for growth and improving market valuation.
- Advancement and Potential Commercialization of Celgosivir for Viral Diseases: The company's pipeline includes Celgosivir, which is under development for COVID-19, RSV, and Dengue. Celgosivir is currently in Phase I clinical development for Respiratory Syncytial Virus (RSV) infections. Preliminary data indicates that Celgosivir may inhibit the replication of SARS-CoV-2 (the virus causing COVID-19) and RSV in cell culture, and potentially protect the lungs from RSV infection in animal models. While its development for dengue has seen some challenges in the past, 60 Degrees Pharmaceuticals is planning a clinical development campaign for its repositioning across these viral illnesses, representing a potential long-term revenue driver as it progresses through clinical trials.
AI Analysis | Feedback
Share Issuance
- The company completed a micro-cap unit Initial Public Offering (IPO) on July 12, 2023, raising $7.5 million by offering 1.42 million units.
- On February 5, 2025, 60 Degrees Pharmaceuticals conducted a registered direct offering and concurrent private placement of common stock and warrants, generating approximately $1.075 million in gross proceeds.
- A public offering was priced on July 15, 2025, aiming to generate approximately $5 million in gross proceeds, with potential for an additional $5 million upon full exercise of associated short-term warrants.
- The company has implemented two reverse stock splits: a 1-for-5 split effective February 24, 2025, and a 1-for-4 split effective January 20, 2026, primarily to maintain compliance with Nasdaq's minimum bid price requirement.
Inbound Investments
- The company secured $7.5 million in capital from its micro-cap unit IPO on July 12, 2023.
- Approximately $5 million in gross proceeds were expected from a public offering priced on July 15, 2025, which also included accompanying warrants that could bring in up to an additional $5 million if fully exercised.
- A registered direct offering and concurrent private placement on February 5, 2025, resulted in approximately $1.075 million in gross proceeds.
Outbound Investments
- In January 2026, 60 Degrees Pharmaceuticals exercised an option to negotiate an exclusive license with Florida State University for large-scale purification techniques of castanospermine.
- The company maintains a patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
Capital Expenditures
- Capital expenditures were approximately $60,000 in the 12 months leading up to March 8, 2026.
- In fiscal year 2024, capital expenditures amounted to $104,000.
- The company is in an investment phase, with expanding operating expenses primarily driven by clinical trial programs and research collaborations.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| With 60 Degrees Pharmaceuticals Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SXTP.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.62 |
| Mkt Cap | 0.3 |
| Rev LTM | 54 |
| Op Inc LTM | 8 |
| FCF LTM | -48 |
| FCF 3Y Avg | -57 |
| CFO LTM | -48 |
| CFO 3Y Avg | -46 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -0.3% |
| Rev Chg 3Y Avg | -2.1% |
| Rev Chg Q | 21.3% |
| QoQ Delta Rev Chg LTM | -0.2% |
| Op Mgn LTM | -410.9% |
| Op Mgn 3Y Avg | -545.3% |
| QoQ Delta Op Mgn LTM | -1.8% |
| CFO/Rev LTM | -371.3% |
| CFO/Rev 3Y Avg | -469.5% |
| FCF/Rev LTM | -376.1% |
| FCF/Rev 3Y Avg | -494.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | 2.7 |
| P/EBIT | 1.4 |
| P/E | 1.5 |
| P/CFO | -0.7 |
| Total Yield | -37.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -89.6% |
| D/E | 0.1 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -13.9% |
| 3M Rtn | -25.2% |
| 6M Rtn | -38.6% |
| 12M Rtn | -0.7% |
| 3Y Rtn | -52.6% |
| 1M Excs Rtn | -14.5% |
| 3M Excs Rtn | -17.7% |
| 6M Excs Rtn | -33.1% |
| 12M Excs Rtn | -14.4% |
| 3Y Excs Rtn | -103.8% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA210607 | ARAKODA | tafenoquine succinate | tablet | 8082018 | |||||
Price Behavior
Price Behavior
| Market Price | $1.50 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/12/2023 | |
| Distance from 52W High | -89.1% | |
| 50 Days | 200 Days | |
| DMA Price | $3.03 | $4.87 |
| DMA Trend | down | down |
| Distance from DMA | -50.5% | -69.2% |
| 3M | 1YR | |
| Volatility | 372.2% | 210.3% |
| Downside Capture | 3.13 | 1.15 |
| Upside Capture | 320.66 | -31.93 |
| Correlation (SPY) | 17.7% | -1.1% |
SXTP Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.98 | 6.59 | 5.12 | 2.66 | -0.11 | 0.42 |
| Up Beta | 10.30 | 4.97 | 6.88 | 3.97 | -0.52 | -0.34 |
| Down Beta | 0.54 | 7.12 | 5.25 | 2.66 | -0.51 | 0.28 |
| Up Capture | -449% | 791% | 202% | 63% | -3% | -7% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 7 | 17 | 23 | 50 | 98 | 266 |
| Down Capture | 254% | 251% | 322% | 215% | 100% | 108% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 13 | 23 | 37 | 67 | 141 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SXTP | |
|---|---|---|---|---|
| SXTP | -80.2% | 209.1% | -0.07 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 0.3% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | -1.1% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 15.5% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -5.6% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -10.2% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 2.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SXTP | |
|---|---|---|---|---|
| SXTP | -73.4% | 170.0% | -0.77 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | -2.8% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | -0.4% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 11.5% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 0.6% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | -3.1% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 4.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SXTP | |
|---|---|---|---|---|
| SXTP | -48.4% | 170.0% | -0.77 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | -2.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | -0.4% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 11.5% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 0.6% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | -3.1% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 4.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/20/2023 | 10-Q |
| 06/30/2023 | 08/25/2023 | 10-Q |
| 03/31/2023 | 07/13/2023 | 424B4 |
| 09/30/2022 | 01/31/2023 | S-1 |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dow, Geoffrey S | President and CEO | Direct | Buy | 12162025 | 0.80 | 9,670 | 7,759 | 47,837 | Form |
| 2 | Dow, Geoffrey S | President and CEO | Direct | Buy | 12122025 | 0.95 | 9,350 | 8,886 | 44,037 | Form |
| 3 | Dow, Geoffrey S | President and CEO | Direct | Buy | 12122025 | 0.92 | 3,613 | 3,318 | 45,872 | Form |
| 4 | Xu, Cheryl | Direct | Buy | 6052025 | 2.88 | 5,000 | 14,410 | 45,582 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.